# Fuse Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fuse-biotherapeutics

- Industry: Biotechnology
- Headquarters: Los Angeles, US
- Website: www.fusebiotx.com
- Total disclosed funding: $9.5M
- Latest round: Seed (Nov 15, 2021)
- Investors on record: 5

## About

Based in California, US, and founded in 2021 by Brian Rabinovich, Evren Alici, Jeffrey Takimoto, and Paul Y. Song, Fuse Biotherapeutics, Inc., a.k.a. FuseBio, develops next-generation immune-modulating therapeutics, which potentiates and directs both adaptive and innate immunity. In November 2021, Fuse Biotherapeutics, Inc. raised USD 9.5 million in seed funding led by Viva BioInnovator, with participation from Sherpa Healthcare Partners, Ivy Venture Group, Sirona Capital, and GC&H Investments. As of November 2021, co-founders Paul Y. Song is the CEO of Fuse Biotherapeutics, Inc.

The company develops transformative immune-modulating therapeutics for cancer patients. In addition, the company also provides a proprietary platform that leverages the inherent capacity of NK cells to distinguish between normal and diseased tissues.

Fuse Biotherapeutics, Inc. plans to use its proceeds from November 2021 funding to develop its proprietary platform.

## Funding rounds

- Seed, Nov 15, 2021, $9.5M — GC&H Investments, Sirona Capital, Sherpa Healthcare Partners, Ivy Ventures, LLC, Viva BioInnovator

## Investors

- GC&H Investments (https://capitalatlas.ai/funds/gc-h-investments) — Seed
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Seed
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Seed
- Ivy Ventures, LLC — Seed
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Seed